{
    "clinical_study": {
        "@rank": "159992", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.   Determine whether polyethylene-glycol-conjugated interleukin 2 (PEG-IL-2)\n      can reduce the number of infections in patients with common variable immunodeficiency.\n\n      II.  Determine whether this therapy can improve lung functions in these patients with\n      pulmonary impairment."
        }, 
        "brief_title": "Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency", 
        "condition": "Common Variable Immunodeficiency", 
        "condition_browse": {
            "mesh_term": [
                "Common Variable Immunodeficiency", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, open-label study.  Patients are randomized to\n      receive polyethylene-glycol-conjugated interleukin 2 (PEG-IL-2) or placebo.\n\n      Patients receive PEG-IL-2 or placebo by subcutaneous injection weekly for 18 months.\n      Patients maintain a daily diary for 24 months.\n\n      Patients are followed every 4 months for 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Documented common variable immunodeficiency defined as a reduction of serum IgG by at\n        least 2 standard deviations\n\n        In vitro lymphocyte proliferative response to PEG-IL-2 of at least 10 times more than\n        unstimulated cultures\n\n        --Prior/Concurrent Therapy--\n\n        No biologic response modifier therapy (i.e., interferon, cyclosporin A) except prednisone\n        (maximum 10 mg/day)\n\n        Concurrent treatment with same dosage intravenous gamma-globulin for at least 6 months is\n        required\n\n        --Patient Characteristics--\n\n        Life expectancy: At least 24 months\n\n        Other: Not pregnant or nursing HIV negative"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": "48", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004695", 
            "org_study_id": "199/13358", 
            "secondary_id": [
                "MTS-93-726-ME", 
                "MTS-FDR001162"
            ]
        }, 
        "intervention": {
            "intervention_name": "PEG-interleukin-2", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Interleukin-2"
        }, 
        "keyword": [
            "common variable immunodeficiency", 
            "immunologic disorders and infectious disorders", 
            "primary immunodeficiency disease", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Mount Sinai School of Medicine", 
            "last_name": "Charlotte Cunningham-Rundles", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004695"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Mount Sinai School of Medicine", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 1997", 
        "study_design": "Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1999"
    }, 
    "geocoordinates": {}
}